These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8300137)

  • 1. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells.
    Huang YW; Vitetta ES
    Hybridoma; 1993 Oct; 12(5):621-30. PubMed ID: 8300137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro.
    Goto H; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Ashihara E; Oku N; Inaba T; Fujita N; Koishihara Y
    Jpn J Cancer Res; 1994 Sep; 85(9):958-65. PubMed ID: 7961126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
    Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
    Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies.
    Liautard J; Gaillard JP; Mani JC; Montero-Julian F; Duperray C; Lu ZY; Jourdan M; Klein B; Brailly H; Brochier J
    Eur Cytokine Netw; 1994; 5(3):293-300. PubMed ID: 7524715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
    Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
    Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of flow cytometric detection of cell surface interleukin-6 receptors in human myeloma cell lines.
    Chen YH; Feng XX; Hagen K
    Clin Lab Haematol; 1996 Sep; 18(3):161-9. PubMed ID: 8939386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells.
    Keller ET; Ershler WB
    J Immunol; 1995 Apr; 154(8):4091-8. PubMed ID: 7706747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
    Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
    Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
    Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
    Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
    Gaillard JP; Liautard J; Klein B; Brochier J
    Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
    Lasfar A; Wietzerbin J; Billard C
    Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.
    Diamant M; Hansen MB; Rieneck K; Svenson M; Yasukawa K; Bendtzen K
    Leuk Res; 1996 Apr; 20(4):291-301. PubMed ID: 8642840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R).
    Lust JA; Jelinek DF; Donovan KA; Frederick LA; Huntley BK; Braaten JK; Maihle NJ
    Curr Top Microbiol Immunol; 1995; 194():199-206. PubMed ID: 7895493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
    Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
    J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
    Villunger A; Egle A; Kos M; Hittmair A; Maly K; Greil R
    Int J Cancer; 1996 Feb; 65(4):498-505. PubMed ID: 8621234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.
    Taetle R; Dos Santos B; Ohsugi Y; Koishihara Y; Yamada Y; Messner H; Dalton W
    J Natl Cancer Inst; 1994 Mar; 86(6):450-5. PubMed ID: 8120920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
    Taetle R; Dos Santos B; Akamatsu K; Koishihara Y; Ohsugi Y
    Clin Cancer Res; 1996 Feb; 2(2):253-9. PubMed ID: 9816167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells.
    de Hon FD; Ehlers M; Rose-John S; Ebeling SB; Bos HK; Aarden LA; Brakenhoff JP
    J Exp Med; 1994 Dec; 180(6):2395-400. PubMed ID: 7964514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies against the human interleukin-11 receptor alpha-chain (IL-11Ralpha) and their use in studies of human mononuclear cells.
    Blanc C; Vusio P; Schleinkofer K; Boisteau O; Pflanz S; Minvielle S; Grötzinger J; Müller-Newen G; Heinrich PC; Jacques Y; Montero-Julian FA
    J Immunol Methods; 2000 Jul; 241(1-2):43-59. PubMed ID: 10915848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors.
    Brochier J; Liautard J; Jacquet C; Gaillard JP; Klein B
    Eur J Immunol; 2001 Jan; 31(1):259-64. PubMed ID: 11265642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.